Figure 16 displays a forest plot of studies reporting the relative risk of experiencing gastrointestinal adverse effects in the intervention group compared to the control group. Data from Figure 16 are presented in Appendix C, Tables 2 and 4. This figure is described further in “Results: Key Question 4: Pharmacotherapy: Orlistat: Adverse Events” as follows: “GI-related adverse effects were more common in the orlistat compared to placebo group and were the main cause of excess adverse effects in the orlistat group (Figure 16).”

Figure 16Relative Risk of Experiencing Gastrointestinal Adverse Effects in Orlistat Trials

Abbreviations: CI=confidence interval; CV=cardiovascular; IV=intervention; N=number; RR=relative risk; SD=standard deviation; Subclincl=subclinical; Unsel=unselected.

From: 3, Results

Cover of Screening for and Management of Obesity and Overweight in Adults
Screening for and Management of Obesity and Overweight in Adults [Internet].
Evidence Syntheses, No. 89.
LeBlanc E, O'Connor E, Whitlock EP, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.